| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| TLXTelix Pharmaceuticals Limited | 2.49B | 7.43 | 53.07 | 55.85% | 3.98% | 15.63% | 0.36% | 1.02 |
| EXELExelixis, Inc. | 12.18B | 45.44 | 25.82 | 18.49% | 29.63% | 31.37% | 5.2% | 0.09 |
| BBOTBridgeBio Oncology Therapeutics Inc. | 919.87M | 11.50 | 25 | -25.73% | ||||
| INBXInhibrx Biosciences, Inc. | 1.04B | 71.80 | 0.62 | -88.89% | -110.78% | -421.09% | 0.06 | |
| NUVBNuvation Bio Inc. | 2.1B | 6.14 | -2.91 | -8.13% | -66.74% | 0.02 | ||
| RLAYRelay Therapeutics, Inc. | 1.32B | 7.63 | -3.23 | -60.83% | -26.71% | -48.97% | 0.06 | |
| ORICORIC Pharmaceuticals, Inc. | 1.12B | 11.52 | -6.30 | -33.24% | 0.01 | |||
| ZLABZai Lab Limited | 2.09B | 18.82 | -7.24 | 49.59% | -46.83% | -27.21% | 0.18 |
| Dec 2023 | Dec 2024 | |
|---|---|---|
| Sales/Revenue | 0 | 0 |
| Revenue Growth % | - | - |
| Cost of Goods Sold | 0 | 0 |
| COGS % of Revenue | - | - |
| Gross Profit | 0 | 0 |
| Gross Margin % | - | - |
| Gross Profit Growth % | - | - |
| Operating Expenses | 4.73M | 11.18M |
| OpEx % of Revenue | - | - |
| Selling, General & Admin | 4.54M | 7.65M |
| SG&A % of Revenue | - | - |
| Research & Development | 193.58K | 3.53M |
| R&D % of Revenue | - | - |
| Other Operating Expenses | 0 | 0 |
| Operating Income | -4.73M | -11.18M |
| Operating Margin % | - | - |
| Operating Income Growth % | - | -1.36% |
| EBITDA | -4.73M | -11.16M |
| EBITDA Margin % | - | - |
| EBITDA Growth % | - | -1.36% |
| D&A (Non-Cash Add-back) | 0 | 0 |
| EBIT | -4.73M | -11.16M |
| Net Interest Income | -595.54K | 24.17K |
| Interest Income | 0 | 24.17K |
| Interest Expense | 595.54K | 0 |
| Other Income/Expense | -584.82K | 25.39K |
| Pretax Income | -5.31M | -11.16M |
| Pretax Margin % | - | - |
| Income Tax | 0 | 0 |
| Effective Tax Rate % | 1% | 1% |
| Net Income | -5.31M | -11.16M |
| Net Margin % | - | - |
| Net Income Growth % | - | -1.1% |
| Net Income (Continuing) | -5.31M | -11.16M |
| Discontinued Operations | 0 | 0 |
| Minority Interest | 0 | 0 |
| EPS (Diluted) | -0.67 | -0.90 |
| EPS Growth % | - | -0.34% |
| EPS (Basic) | -0.67 | -0.90 |
| Diluted Shares Outstanding | 8.08M | 11.82M |
| Basic Shares Outstanding | 8.08M | 11.82M |
| Dividend Payout Ratio | - | - |
| Dec 2023 | Dec 2024 | |
|---|---|---|
| Total Current Assets | 1.89M | 5.38M |
| Cash & Short-Term Investments | 1.72M | 4.16M |
| Cash Only | 1.72M | 4.16M |
| Short-Term Investments | 0 | 0 |
| Accounts Receivable | 0 | 0 |
| Days Sales Outstanding | - | - |
| Inventory | 0 | 0 |
| Days Inventory Outstanding | - | - |
| Other Current Assets | 0 | 0 |
| Total Non-Current Assets | 0 | 268.41K |
| Property, Plant & Equipment | 0 | 268.41K |
| Fixed Asset Turnover | - | - |
| Goodwill | 0 | 0 |
| Intangible Assets | 0 | 0 |
| Long-Term Investments | 0 | 0 |
| Other Non-Current Assets | 0 | 0 |
| Total Assets | 1.89M | 5.64M |
| Asset Turnover | - | - |
| Asset Growth % | - | 1.98% |
| Total Current Liabilities | 781.61K | 2.3M |
| Accounts Payable | 210.84K | 1.28M |
| Days Payables Outstanding | - | - |
| Short-Term Debt | 0 | 116.25K |
| Deferred Revenue (Current) | 0 | 0 |
| Other Current Liabilities | 27.77K | 761.53K |
| Current Ratio | 2.42x | 2.33x |
| Quick Ratio | 2.42x | 2.33x |
| Cash Conversion Cycle | - | - |
| Total Non-Current Liabilities | 0 | 205.82K |
| Long-Term Debt | 0 | 0 |
| Capital Lease Obligations | 0 | 205.82K |
| Deferred Tax Liabilities | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 |
| Total Liabilities | 781.61K | 2.51M |
| Total Debt | 0 | 322.08K |
| Net Debt | -1.72M | -3.84M |
| Debt / Equity | - | 0.10x |
| Debt / EBITDA | - | - |
| Net Debt / EBITDA | - | - |
| Interest Coverage | -7.94x | - |
| Total Equity | 1.11M | 3.13M |
| Equity Growth % | - | 1.82% |
| Book Value per Share | 0.14 | 0.27 |
| Total Shareholders' Equity | 1.11M | 3.13M |
| Common Stock | 18.76M | 30.5M |
| Retained Earnings | -17.75M | -28.89M |
| Treasury Stock | 0 | 0 |
| Accumulated OCI | 0 | 0 |
| Minority Interest | 0 | 0 |
| Dec 2023 | Dec 2024 | |
|---|---|---|
| Cash from Operations | -4.16M | -10.25M |
| Operating CF Margin % | - | - |
| Operating CF Growth % | - | -1.46% |
| Net Income | -5.31M | -11.16M |
| Depreciation & Amortization | 0 | 0 |
| Stock-Based Compensation | 98.58K | 713.12K |
| Deferred Taxes | 0 | 0 |
| Other Non-Cash Items | 584.82K | 162.24K |
| Working Capital Changes | 473.1K | 32.93K |
| Change in Receivables | 0 | 0 |
| Change in Inventory | 0 | 0 |
| Change in Payables | 79.09K | 808.75K |
| Cash from Investing | 0 | 0 |
| Capital Expenditures | 0 | 0 |
| CapEx % of Revenue | - | - |
| Acquisitions | - | - |
| Investments | - | - |
| Other Investing | 0 | 0 |
| Cash from Financing | 5.61M | 12.69M |
| Debt Issued (Net) | - | - |
| Equity Issued (Net) | - | - |
| Dividends Paid | 0 | 0 |
| Share Repurchases | - | - |
| Other Financing | 5.11M | 0 |
| Net Change in Cash | - | - |
| Free Cash Flow | -4.16M | -10.25M |
| FCF Margin % | - | - |
| FCF Growth % | - | -1.46% |
| FCF per Share | -0.51 | -0.87 |
| FCF Conversion (FCF/Net Income) | 0.78x | 0.92x |
| Interest Paid | 0 | 40.56K |
| Taxes Paid | 0 | 0 |
| Metric | 2023 | 2024 |
|---|---|---|
| Return on Equity (ROE) | -478.18% | -525.67% |
| Debt / Equity | - | 0.10x |
| Interest Coverage | -7.94x | - |
| FCF Conversion | 0.78x | 0.92x |
Medicus Pharma Ltd. (MDCXW) grew revenue by 0.0% over the past year. Growth has been modest.
Medicus Pharma Ltd. (MDCXW) reported a net loss of $29.5M for fiscal year 2024.
Medicus Pharma Ltd. (MDCXW) has a return on equity (ROE) of -525.7%. Negative ROE indicates the company is unprofitable.
Medicus Pharma Ltd. (MDCXW) had negative free cash flow of $19.3M in fiscal year 2024, likely due to heavy capital investments.